Results for "consumer data right"
451-460 of 560 results for 'consumer data right'
What Aristocrat means for computer-implemented patents
Software companies such as Atlassian, Canva and Rokt are hailed as success stories of Australian innovation. However, for at least the past decade, it has been difficult to protect the value of invest ...
The COVID-19 pandemic – what employers in Vietnam need to know
The Covid-19 pandemic is not only a health crisis in the global community, but has caused widespread economic disruption to all companies and governments around the world. As have governments in other countries, the Government of Vietnam has issued various restrictions and regulations ...
FIRB changes to note from 1 July 2023
In this Insight, we outline and comment on the New Register and corresponding reporting obligations. ...
ASIC's New Document Production Guidelines
ASIC has released its new Document Production Guidelines, which govern how it expects electronic and hard copy records to be produced in response to compulsory notices. ...
ASIC ramps up greenwashing-related regulatory interventions, targeting managed funds and ASX listed entities
ASIC's latest report, ASIC's recent greenwashing interventions (the Report), outlines its recent surveillance activities and regulatory interventions to tackle misleading marketing and greenwashing. ...
Changes to open and transparent sale process requirement for foreign persons acquiring agricultural land
On 25 September 2018 the Foreign Investment Review Board released revised guidance on the application of the requirement for an open and transparent sale process for foreign persons acquiring agricultural land Partner Wendy Rae Senior Associate Julian Barendse and Lawyer Bianca Sacco examine these ...
The pitfalls of pre-emptive rights
In this Insight, we consider an alternative approach that may better balance the rights of selling and non-selling investors where a pre-emptive right remains appropriate. ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
Regulatory scrutiny of private capital increases
Private capital is becoming a growing focus of regulators, both in Australia and internationally, given the ever-increasing flow of capital to the sector in recent years. ...